MOSCOW (MRC) -- Repsol announced the launch of its new Healthcare portfolio, including a total of 28 grades comprised of polypropylene, polyethylene and EVA copolymers, according to GV.
Repsol says the new product offering is based on its existing strengths, including its experience in manufacturing products with the maximum cleanliness, in food contact packaging as well as its commitment to continuous improvement.
In addition, the company’s propylene glycol USP/EP (pharmaceutical grade) is qualified for use as an excipient in pharmaceutical products.
For Repsol, adding the "Guarantee, Commitment and Service component" (GCS) to its products is key to supplying to the pharmaceutical packaging and medical devices segments, adapting to their respective levels of risk through specific service packs. The company’s "Pharma facilities" are located in the Tarragona and Puertollano sites in Spain.
As MRC reported earlier, in Q2 2016, Repsol completed the construction work of its new metallocene polyethelene plant at its Tarragona site. Repsol also started up the plant and began production and marketing of this new product in Q2 2016. Metallocene linear low density polyethylene (mLLDPE) offers very appealing features when transformed into film, such as high transparency and high gloss. Due to its extraordinary tear and puncture resistance it is ideal for packaging applications. Metallocene linear low density polyethylene enhances the wide range of products already offered by Repsol adding to its low and high density polyethylene, EVA and EBA copolymers as well as polypropylene grades. With this new investment, Repsol reinforces its commitment to its customers by offering differentiated products that provide high added value and boosts their strengths to increase their competitiveness.
Repsol S.A is an integrated Spanish oil and gas company with operations in 28 countries. The bulk of its assets are located in Spain.